PandemieGrippaleV1, PubMed, Curation, bibRecord, 001E42

Cost-benefit of stockpiling drugs for influenza pandemic.

Identifieur interne : 001E42 ( PubMed/Curation ); précédent : 001E41; suivant : 001E43

Cost-benefit of stockpiling drugs for influenza pandemic.

Auteurs : Ran D. Balicer [Israël] ; Michael Huerta ; Nadav Davidovitch ; Itamar Grotto

Source :

Emerging infectious diseases [ 1080-6040 ] ; 2005.

RBID : pubmed:16102319

Descripteurs français

KwdFr :
- Acétamides (usage thérapeutique), Acétamides (économie), Adolescent, Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Antiviraux (usage thérapeutique), Antiviraux (économie), Enfant, Enfant d'âge préscolaire, Flambées de maladies (économie), Grippe humaine (traitement médicamenteux), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains, Israël (épidémiologie), Modèles biologiques, Modèles économiques, Nourrisson, Organisation mondiale de la santé, Oséltamivir, Sujet âgé.
MESH :
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Acétamides, Antiviraux.
- économie : Acétamides, Antiviraux, Flambées de maladies, Grippe humaine.
- épidémiologie : Grippe humaine, Israël.
- Adolescent, Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Enfant, Enfant d'âge préscolaire, Humains, Modèles biologiques, Modèles économiques, Nourrisson, Organisation mondiale de la santé, Oséltamivir, Sujet âgé.
Wicri :
- geographic : Israël.

English descriptors

KwdEn :
- Acetamides (economics), Acetamides (therapeutic use), Adolescent, Adult, Aged, Antiviral Agents (economics), Antiviral Agents (therapeutic use), Child, Child, Preschool, Cost-Benefit Analysis, Disease Outbreaks (economics), Humans, Infant, Influenza, Human (drug therapy), Influenza, Human (economics), Influenza, Human (epidemiology), Israel (epidemiology), Middle Aged, Models, Biological, Models, Economic, Oseltamivir, World Health Organization.
MESH :
- chemical , economics : Acetamides, Antiviral Agents.
- chemical , therapeutic use : Acetamides, Antiviral Agents.
- geographic , epidemiology : Israel.
- drug therapy : Influenza, Human.
- economics : Disease Outbreaks, Influenza, Human.
- epidemiology : Influenza, Human.
- Adolescent, Adult, Aged, Child, Child, Preschool, Cost-Benefit Analysis, Humans, Infant, Middle Aged, Models, Biological, Models, Economic, Oseltamivir, World Health Organization.

Abstract

We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.

DOI: 10.3201/eid1108.041156
PubMed: 16102319

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E42

Links to Exploration step

pubmed:16102319

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-benefit of stockpiling drugs for influenza pandemic.</title>
<author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D" last="Balicer">Ran D. Balicer</name>
<affiliation wicri:level="1"><nlm:affiliation>Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name>
</author>
<author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name>
</author>
<author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16102319</idno>
<idno type="pmid">16102319</idno>
<idno type="doi">10.3201/eid1108.041156</idno>
<idno type="wicri:Area/PubMed/Corpus">001E42</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E42</idno>
<idno type="wicri:Area/PubMed/Curation">001E42</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E42</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-benefit of stockpiling drugs for influenza pandemic.</title>
<author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D" last="Balicer">Ran D. Balicer</name>
<affiliation wicri:level="1"><nlm:affiliation>Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Ministry of Health, Jerusalem</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name>
</author>
<author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name>
</author>
<author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name>
</author>
</analytic>
<series><title level="j">Emerging infectious diseases</title>
<idno type="ISSN">1080-6040</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (economics)</term>
<term>Acetamides (therapeutic use)</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Antiviral Agents (economics)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cost-Benefit Analysis</term>
<term>Disease Outbreaks (economics)</term>
<term>Humans</term>
<term>Infant</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (economics)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Israel (epidemiology)</term>
<term>Middle Aged</term>
<term>Models, Biological</term>
<term>Models, Economic</term>
<term>Oseltamivir</term>
<term>World Health Organization</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acétamides (usage thérapeutique)</term>
<term>Acétamides (économie)</term>
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse coût-bénéfice</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Antiviraux (économie)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Flambées de maladies (économie)</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (économie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Israël (épidémiologie)</term>
<term>Modèles biologiques</term>
<term>Modèles économiques</term>
<term>Nourrisson</term>
<term>Organisation mondiale de la santé</term>
<term>Oséltamivir</term>
<term>Sujet âgé</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Israel</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Disease Outbreaks</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acétamides</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Acétamides</term>
<term>Antiviraux</term>
<term>Flambées de maladies</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Israël</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Infant</term>
<term>Middle Aged</term>
<term>Models, Biological</term>
<term>Models, Economic</term>
<term>Oseltamivir</term>
<term>World Health Organization</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse coût-bénéfice</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Humains</term>
<term>Modèles biologiques</term>
<term>Modèles économiques</term>
<term>Nourrisson</term>
<term>Organisation mondiale de la santé</term>
<term>Oséltamivir</term>
<term>Sujet âgé</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Israël</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16102319</PMID>
<DateCompleted><Year>2005</Year>
<Month>10</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1080-6040</ISSN>
<JournalIssue CitedMedium="Print"><Volume>11</Volume>
<Issue>8</Issue>
<PubDate><Year>2005</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Emerging infectious diseases</Title>
<ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cost-benefit of stockpiling drugs for influenza pandemic.</ArticleTitle>
<Pagination><MedlinePgn>1280-2</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Balicer</LastName>
<ForeName>Ran D</ForeName>
<Initials>RD</Initials>
<AffiliationInfo><Affiliation>Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Huerta</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Davidovitch</LastName>
<ForeName>Nadav</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Grotto</LastName>
<ForeName>Itamar</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Emerg Infect Dis</MedlineTA>
<NlmUniqueID>9508155</NlmUniqueID>
<ISSNLinking>1080-6040</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>10</Month>
<Day>12</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16102319</ArticleId>
<ArticleId IdType="pmc">PMC3320484</ArticleId>
<ArticleId IdType="doi">10.3201/eid1108.041156</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2002 Jan;40(1):84-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11773097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2003 Jan;9(1):1-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12691538</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2003 Jun 7;326(7401):1235</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12791735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 2004 Apr 1;159(7):623-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15033640</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2004 Apr 1;38(7):925-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034821</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2004 Mar 12;79(11):107-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15114955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2004 Jun 12;328(7453):1391-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15191958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 2004 Apr;82(4):242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15259251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 2004 Apr;82(4):317-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15309817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Epidemiol. 1984 Mar;13(1):112-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6698695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1989 Dec 21;321(25):1696-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2687687</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1999 Jul 7;282(1):31-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10404908</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 1999 Sep-Oct;5(5):659-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10511522</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1999 Oct 28;341(18):1336-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10536125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2005 Mar 5;330(7490):495</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15746113</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Am. 2005 May;292(5):20, 22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15882011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 2003 Jul 28;163(14):1667-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885681</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2000 Feb 23;283(8):1016-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10697061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2000 Nov;48(2):101-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11114412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2001;61(2):263-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11270942</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E42 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001E42 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:16102319
   |texte=   Cost-benefit of stockpiling drugs for influenza pandemic.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:16102319" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Cost-benefit of stockpiling drugs for influenza pandemic.

Cost-benefit of stockpiling drugs for influenza pandemic.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki